Ommelander Ziekenhuis Groningen B.V.
- Address
- Pastorieweg 1, 9679 BJ Scheemda, The Netherlands
Ommelander Ziekenhuis Groningen B.V.
Ommelander Ziekenhuis Groningen B.V. is a clinical research center with expertise in personalized medicine approaches across multiple therapeutic areas. The institution demonstrates particular strength in optimizing treatment strategies through genotype-guided therapies and individualized dosing regimens, with a focus on improving patient outcomes while minimizing adverse events.
- Multiple Sclerosis treatment optimization through personalized dosing of disease-modifying therapies including ocrelizumab and natalizumab
- Cardiovascular and peripheral vascular disease management with genotype-guided antithrombotic therapy
- Hematologic malignancies and oncology, including multiple myeloma treatment strategies and dose-optimized chemotherapy for advanced colorectal cancer
The center's research portfolio reflects a commitment to precision medicine and patient-centered care, particularly for complex patient populations including older adults and those requiring long-term disease management. Their investigations into treatment-free intervals and extended dosing schedules demonstrate innovation in reducing treatment burden while maintaining therapeutic efficacy across neurological, oncological, and cardiovascular conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ommelander Ziekenhuis Groningen B.V.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Phase III | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 2 | Unknown | 2024-10-14 | 2026-07-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.